Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease
- Author
- BEGLINGER, Leigh J1 ; ADAMS, Williams H1 ; PAULSON, Henry2 ; FIEDOROWICZ, Jess G1 ; LANGBEHN, Douglas R1 ; DUFF, Kevin1 ; LESERMAN, Anne1 ; PAULSEN, Jane S1
[1] Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, United States
[2] Department of Neurology, University of Michigan, Ann Arbor, MI, United States - Source
Journal of clinical psychopharmacology. 2009, Vol 29, Num 5, pp 484-487, 4 p ; ref : 28 ref
- CODEN
- JCPYDR
- ISSN
- 0271-0749
- Scientific domain
- Cognition; Pharmacology drugs; Psychology, psychopathology, psychiatry
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Atomoxétine Chorée de Huntington Essai thérapeutique contrôlé Homme Précoce Psychotrope Trouble cognitif Catécholamine Inhibiteur recapture Maladie dégénérative Maladie héréditaire Neurotransmetteur Noradrénaline Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Syndrome extrapyramidal
- Keyword (en)
- Atomoxetine Huntington disease Controlled therapeutic trial Human Early Psychotropic Cognitive disorder Catecholamine Reuptake inhibitor Degenerative disease Genetic disease Neurotransmitter Norepinephrine Cerebral disorder Central nervous system disease Nervous system diseases Extrapyramidal syndrome
- Keyword (es)
- Atomoxetina Corea Huntington Ensayo terapéutico controlado Hombre Precoz Psicotropo Trastorno cognitivo Catecolamina Inhibidor recaptura Enfermedad degenerativa Enfermedad hereditaria Neurotransmisor Noradrenalina Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Extrapiramidal síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17A Nervous system (semeiology, syndromes) / 002B17A01 Nervous system as a whole
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B18 Psychopathology. Psychiatry / 002B18C Adult and adolescent clinical studies / 002B18C13 Organic mental disorders. Neuropsychology
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-D Psychopathology. Psychiatry / 770-D03 Adult and adolescent clinical studies / 770-D03M Organic mental disorders. Neuropsychology
- Discipline
- Neurology Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 22289022
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1097/JCP.0b013e3181b2ac0a 
https://dx.doi.org/10.1097/JCP.0b013e3181b2ac0a
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"484\";s:8:\"\u0000*\u0000epage\";s:3:\"487\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BEGLINGER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Leigh J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"ADAMS, Williams H\";i:1;s:14:\"PAULSON, Henry\";i:2;s:19:\"FIEDOROWICZ, Jess G\";i:3;s:19:\"LANGBEHN, Douglas R\";i:4;s:11:\"DUFF, Kevin\";i:5;s:14:\"LESERMAN, Anne\";i:6;s:15:\"PAULSEN, Jane S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"484\";s:8:\"\u0000*\u0000epage\";s:3:\"487\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BEGLINGER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Leigh J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"ADAMS, Williams H\";i:1;s:14:\"PAULSON, Henry\";i:2;s:19:\"FIEDOROWICZ, Jess G\";i:3;s:19:\"LANGBEHN, Douglas R\";i:4;s:11:\"DUFF, Kevin\";i:5;s:14:\"LESERMAN, Anne\";i:6;s:15:\"PAULSEN, Jane S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"484\";s:8:\"\u0000*\u0000epage\";s:3:\"487\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BEGLINGER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Leigh J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"ADAMS, Williams H\";i:1;s:14:\"PAULSON, Henry\";i:2;s:19:\"FIEDOROWICZ, Jess G\";i:3;s:19:\"LANGBEHN, Douglas R\";i:4;s:11:\"DUFF, Kevin\";i:5;s:14:\"LESERMAN, Anne\";i:6;s:15:\"PAULSEN, Jane S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"484\";s:8:\"\u0000*\u0000epage\";s:3:\"487\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BEGLINGER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Leigh J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"ADAMS, Williams H\";i:1;s:14:\"PAULSON, Henry\";i:2;s:19:\"FIEDOROWICZ, Jess G\";i:3;s:19:\"LANGBEHN, Douglas R\";i:4;s:11:\"DUFF, Kevin\";i:5;s:14:\"LESERMAN, Anne\";i:6;s:15:\"PAULSEN, Jane S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1097\/JCP.0b013e3181b2ac0a\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Journal of clinical psychopharmacology\";s:9:\"\u0000*\u0000stitle\";s:24:\"J. clin. psychopharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:2:\"29\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"484\";s:8:\"\u0000*\u0000epage\";s:3:\"487\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0271-0749\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BEGLINGER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Leigh J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:17:\"ADAMS, Williams H\";i:1;s:14:\"PAULSON, Henry\";i:2;s:19:\"FIEDOROWICZ, Jess G\";i:3;s:19:\"LANGBEHN, Douglas R\";i:4;s:11:\"DUFF, Kevin\";i:5;s:14:\"LESERMAN, Anne\";i:6;s:15:\"PAULSEN, Jane S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JCPYDR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
